Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
Steven G. Potkin, John M. Kane, Christoph U. Correll, et al.
Schizophrenia (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 283

Showing 1-25 of 283 citing articles:

Treatment resistance in psychiatry: state of the art and new directions
Oliver Howes, Michael E. Thase, Toby Pillinger
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 58-72
Open Access | Times Cited: 266
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Jean Claude Martel, Silvia Gatti McArthur
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 191
The clinical significance of duration of untreated psychosis: an umbrella review and random‐effects meta‐analysis
Oliver Howes, Thomas Whitehurst, Ekaterina Shatalina, et al.
World Psychiatry (2021) Vol. 20, Iss. 1, pp. 75-95
Open Access | Times Cited: 160
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
Christoph U. Correll, Ofer Agid, Benedicto Crespo‐Facorro, et al.
CNS Drugs (2022) Vol. 36, Iss. 7, pp. 659-679
Open Access | Times Cited: 97
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 7, pp. 2950-2967
Closed Access | Times Cited: 81
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 54
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 43
Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions
Aristotle N. Voineskos, Colin Hawco, Nicholas H. Neufeld, et al.
World Psychiatry (2024) Vol. 23, Iss. 1, pp. 26-51
Open Access | Times Cited: 28
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 18
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis
Johannes Schneider‐Thoma, Tasnim Hamza, Konstantina Chalkou, et al.
The Lancet Psychiatry (2025)
Open Access | Times Cited: 2
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Markku Lähteenvuo, Jari Tiihonen
Drugs (2021) Vol. 81, Iss. 11, pp. 1273-1284
Open Access | Times Cited: 94
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
Nina Dedic, Heather Dworak, Courtney Zeni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13185-13185
Open Access | Times Cited: 78
The impact of duration of illness on treatment nonresponse and drop‐out: Exploring the relevance of enduring eating disorder concept
Fernando Fernández‐Aranda, Janet Treasure, Georgios Paslakis, et al.
European Eating Disorders Review (2021) Vol. 29, Iss. 3, pp. 499-513
Closed Access | Times Cited: 71
Sex differences in the blood–brain barrier: Implications for mental health
Laurence Dion‐Albert, Luisa Bandeira Binder, Béatrice Daigle, et al.
Frontiers in Neuroendocrinology (2022) Vol. 65, pp. 100989-100989
Open Access | Times Cited: 63
Astrocytes in schizophrenia
Tina Notter
Brain and Neuroscience Advances (2021) Vol. 5
Open Access | Times Cited: 61
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
More than a biomarker: could language be a biosocial marker of psychosis?
Lena Palaniyappan
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 56
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 52
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Daisy L. Spark, Alex Fornito, Christopher J. Langmead, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice
Benneth Ben‐Azu, Olusegun G. Adebayo, Theophilus Aghogho Jarikre, et al.
Metabolic Brain Disease (2022) Vol. 37, Iss. 8, pp. 2807-2826
Closed Access | Times Cited: 43
Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis
Hiroshi Komatsu, Goh Onoguchi, Stefan Jerotić, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 9, pp. 3592-3616
Closed Access | Times Cited: 42
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment
Andrea de Bartolomeis, Giuseppe De Simone, Michele De Prisco, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 7, pp. 2811-2825
Open Access | Times Cited: 23
The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction
Neha S. Rawani, Allen W. Chan, Serdar Dursun, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 709-709
Open Access | Times Cited: 11
Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia
Brandon Cilia, Dhamidhu Eratne, Cassandra Wannan, et al.
Australian & New Zealand Journal of Psychiatry (2025)
Open Access | Times Cited: 1
The hypothesis of biologically based subtypes of schizophrenia: a 10‐year update
Oliver Howes, Bernard R Bukala, Sameer Jauhar, et al.
World Psychiatry (2025) Vol. 24, Iss. 1, pp. 46-47
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top